{
    "id": "7803166",
    "text": "Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.http://www.sanofi- aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009 ==See also== * GR-159,897 * Ibodutant * Nepadutant ==References== Category:Antidepressants Category:Anxiolytics Category:NK2 receptor antagonists Category:Acetanilides Category:Piperidines Category:Chloroarenes Category:Benzamides Category:Experimental drugs ",
    "title": "Saredutant"
}